Form 4: Fortress Biotech CFO David Jin Reports Transaction in Series A Preferred Stock
SEC Form 4 Filing
David Jin, CFO of Fortress Biotech, reports the acquisition and disposal of 500 shares of Series A Cumulative Perpetual Preferred Stock on July 10, 2024.
Summary
- On July 10, 2024, David Jin, the Chief Financial Officer of Fortress Biotech, Inc. (FBIO), engaged in a transaction involving Series A Cumulative Perpetual Preferred Stock.
- Jin acquired 500 shares at a price of $7.5 per share and disposed of 500 shares.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to an insider transaction. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO in this case, trade their company's securities. It provides transparency into the transactions of company leadership.
Stakeholder Impact
- The transaction may provide stakeholders with insights into the actions of company leadership.
Key Dates
| Date | Description |
|---|---|
| 07/10/2024 | Date of transaction involving Series A Cumulative Perpetual Preferred Stock |
| 07/12/2024 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.